Log In
Print
BCIQ
Print
Print this Print this
 

ODM-201

  Manage Alerts
Collapse Summary General Information
Company Orion Corp.
DescriptionOral androgen receptor inhibitor
Molecular Target Androgen receptor
Mechanism of ActionAndrogen receptor inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC); Treat non-metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner

Bayer AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today